Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation

Journal of Clinical Oncology

Volumn 31, Issue 11, 2013, Pages 1442-1449

  Visco, Carlo ^a   Finotto, Silvia ^a   Zambello, Renato ^b   Paolini, Rossella ^c   Menin, Andrea ^a   Zanotti, Roberta ^d   Zaja, Francesco ^e   Semenzato, Gianpietro ^b   Pizzolo, Giovanni ^d   D'Amore, Emanuele S G ^a   Rodeghiero, Francesco ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

^b UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^c SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CYTARABINE; RITUXIMAB;

ADULT; AGE DISTRIBUTION; AGED; ALOPECIA; ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DESQUAMATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART DISEASE; HISTOPATHOLOGY; HUMAN; INFECTION; INFUSION RELATED REACTION; MALE; MANTLE CELL INTERNATIONAL PROGNOSTIC INDEX SCORE; MANTLE CELL NON HODGKIN LYMPHOMA; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHODGKIN LYMPHOMA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STEM CELL MOBILIZATION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKOPENIA; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; NITROGEN MUSTARD COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; REMISSION INDUCTION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VOMITING;

EID: 84875606235     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.9842     Document Type: Article

References (35)

1. Herrmann A, Hoster E, Zwingers T, et al: Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 27:511-518, 2009
2. Romaguera JE, Fayad L, Rodriguez MA, et al: High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23:7013-7023, 2005
3. Gianni AM, Magni M, Martelli M, et al: Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 102:749-755, 2003 (Pubitemid 36842002)
4. Geisler CH, Kolstad A, Laurell A, et al: Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112:2687-2693, 2008
5. Kluin-Nelemans HC, and Doorduijn JK: Treatment of elderly patients with mantle cell lymphoma. Semin Hematol 48:208-213, 2011
6. Ghielmini M, Zucca E: How I treat mantle cell lymphoma. Blood 114:1469-1476, 2009
7. Dreyling M, Kluin-Nelemans HC, Beà S, et al: Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: Report of the 10th annual conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma 52:2226-2236, 2011
8. Lenz G, Dreyling M, Hoster E, et al: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23:1984-1992, 2005 (Pubitemid 46211378)
9. Rummel MJ, Al-Batran SE, Kim SZ, et al: Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 23:3383-3389, 2005
10. Robinson KS, Williams ME, Cohen P, et al: Bendamustine HCl (TREANDA) treatment in combination with rituximab results in objective responses in patients with refractory/relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma: Results from phase II multicenter study (SDX-105-02). Blood 106, 2005 (abstr 923)
11. Rummel MJ, Niederle N, Maschmeyer G, et al: Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. J Clin Oncol 30:6s, 2012 (suppl; abstr 3)
12. Castegnaro S, Visco C, Chieregato K, et al: Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines. Leuk Lymphoma 53:2262-2268, 2012
13. Visco C, Castegnaro S, Chieregato K, et al: The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma. Blood Cells Mol Dis 48:68-75, 2012
14. Chow KU, Sommerlad WD, Boehrer S, et al: Anti-CD20 antibody (IDEC-C2B8, tiruximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement, and caspases. Haematologica 87:33-43, 2002 (Pubitemid 34101111)
15. Lazzarino M, Arcaini L, Bernasconi P, et al: A sequence of immuno-chemotherapy with rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol 116:229-235, 2002 (Pubitemid 34122085)
16. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007 (Pubitemid 350002966)
17. Herold M, Haas A, Srock S, et al: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group hematology and oncology study. J Clin Oncol 25:1986-1992, 2007 (Pubitemid 46972781)
18. Kahl BS, Longo WL, Eickhoff JC, et al: Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: A pilot study from the Wisconsin Oncology Network. Ann Oncol 17:1418-1423, 2006
19. Forstpointner R, Unterhalt M, Dreyling M, et al: Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108:4003-4008, 2006 (Pubitemid 44920177)
20. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
21. Howard OM, Gribben JG, Neuberg DS, et al: Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression free survival. J Clin Oncol 20:1288-1294, 2002 (Pubitemid 34177435)
22. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
23. Hosein PJ, Pastorini VH, Paes FM, et al: Utility of positron emission tomography scans in mantle cell lymphoma. Am J Hematol 86:841-845, 2011
24. Mato AR, Svoboda J, Feldman T, et al: Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD. Cancer 118:3565-3570, 2012
25. Ruan J, Martin P, Furman RR, et al: Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 29:690-697, 2011
26. Houot R, Le Gouill S, Ojeda Uribe M, et al: Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: Results of a phase II trial from the GOELAMS. Ann Oncol 23:1555-1561, 2012
27. Ansell SM, Tang H, Kurtin PJ, et al: Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: A phase 2 study. Lancet Oncol 12:361-368, 2011
28. Renner C, Zinzani PL, Gressin R, et al: A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 97:1085-1091, 2012
29. Zaja F, De Luca S, Vitolo U, et al: Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: Clinical results and effects on microenvironment and neoangiogenic biomarkers. Haematologica 97:416-422, 2012
30. Habermann TM, Lossos IS, Justice G, et al: Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 145:344-349, 2009
31. Kouroukis CT, Fernandez LA, Crump M, et al: A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leuk Lymphoma 52:394-399, 2011
32. Baiocchi RA, Alinari L, Lustberg ME, et al: Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer [epub ahead of print December 14, 2010]
33. Goy A, Bernstein SH, Kahl BS, et al: Bortezomib in patients with relapsed or refractory mantle cell lymphoma: Updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 20:520-525, 2009
34. Lamm W, Kaufmann H, Raderer M, et al: Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica 96:1008-1014, 2011
35. Pott C, Hoster E, Delfau-Larue MH, et al: Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: A European MCL intergroup study. Blood 115:3215-3223, 2010